Related Experiment Video
Updated: May 28, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and
Haoxiang Li1, Min Hou2, Shasha Sun1
1School of Biomedical Sciences, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China.
Abstract:
The cGAS-STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic potential is often limited by the inefficient cytosolic delivery of agonists and the immunosuppressive tumor microenvironment (TME). Here, we report a DNA nanostructure-based platform that simultaneously induces lysosomal degradation of immune checkpoint protein PD-L1 and activates the STING pathway. We demonstrate that STING activation further enhances PD-L1 degradation, resulting in strong synergistic immune activation. In murine models of triple-negative breast cancer, the DNA nanodevice effectively reprograms the TME by enhancing dendritic cell maturation and CD8+ T cell infiltration, resulting in potent suppression of both primary tumor growth and pulmonary metastases. This study establishes a versatile nanoplatform that bridges targeted protein degradation with STING-mediated innate immune activation, provides a promise strategy for cancer immunotherapy.
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
